6.2 Emergency Department Evaluation & Diagnostic Time Goals

Emergency Department Evaluation & Diagnostic Time Goals

Arrival and Immediate Stroke Team Activation

When a patient suffering from a suspected acute ischemic stroke arrives at the emergency department (ED), their evaluation and management must proceed with absolute urgency and synchronized precision. Acute stroke is treated with the same intense operational priority as a major trauma or a cardiac arrest. If the EMS crew provided pre-notification, the hospital's specialized Stroke Team should ideally be waiting in the ambulance bay or the designated resuscitation room upon the patient's arrival.

If the patient arrives via private vehicle, or if EMS arrives without providing advance notice, ED triage personnel must immediately recognize the stroke symptoms and manually trigger the internal Stroke Team activation protocol. The Stroke Team typically operates as a highly choreographed unit, comprising emergency physicians, vascular neurologists, specialized stroke nurses, pharmacists, and radiology technicians. These professionals work in a parallel, rather than sequential, fashion to drastically compress the time required to evaluate the patient and initiate therapy.

Critical Diagnostic Time Goals

The American Heart Association (AHA) and the American Stroke Association (ASA) have established stringent, evidence-based time goals for the evaluation and treatment of acute stroke patients in the ED. These metrics are continuously tracked by hospitals as key performance indicators. They are designed to ensure that eligible patients receive reperfusion therapies as rapidly as possible, thereby minimizing the volume of infarcted brain tissue.

The essential ED time targets include:

• Door-to-provider evaluation: ≤ 10 minutes. Within 10 minutes of crossing the hospital threshold, the patient must be evaluated by a qualified physician or advanced practice provider. This includes a rapid primary survey (Airway, Breathing, Circulation) and the initiation of a structured neurological exam.
• Door-to-stroke team activation: ≤ 15 minutes. The specialized stroke team must be fully notified and actively responding to the patient's bedside.
• Door-to-CT completion: ≤ 20 minutes. The patient must be transported to the radiology department, and the initial neuroimaging study must be physically completed. Meeting this goal often requires bypassing standard ED triage beds and taking the patient directly from the EMS stretcher to the CT scanner.
• Door-to-CT interpretation: ≤ 45 minutes. An expert interpretation of the neuroimaging (typically by a neuroradiologist or a trained emergency physician/neurologist) must be available to guide clinical decision-making.
• Door-to-needle (IV fibrinolytic therapy): ≤ 60 minutes. For patients eligible for IV thrombolysis, the medication must be infusing within 60 minutes of arrival. High-performing stroke centers aggressively target a stretch goal of ≤ 45 minutes for a large percentage of their patients.

The Mandatory Role of Neuroimaging

The single most critical diagnostic test in the initial evaluation of an acute stroke patient is an emergent brain imaging study. The standard of care is an immediate, non-contrast head Computed Tomography (CT) scan. While some advanced centers utilize emergent Magnetic Resonance Imaging (MRI) protocols, the non-contrast CT remains the universally accepted, fastest, and most accessible modality.

Ruling out Intracranial Hemorrhage

It is vital to understand that the primary purpose of this initial, urgent non-contrast head CT is not to positively identify an ischemic stroke, but rather to definitively rule out an intracranial hemorrhage (bleeding within the cranial vault). Ischemic strokes, especially in their early stages, are often completely invisible on a non-contrast CT for several hours after symptom onset. However, any significant intracranial hemorrhage will appear immediately as a bright, hyperdense area on the scan.

Ruling out hemorrhage is the mandatory, non-negotiable gatekeeper step before any reperfusion therapy can proceed. Fibrinolytic therapy (thrombolytics or "clot-busters") is absolutely contraindicated in patients with an intracranial hemorrhage. Administering a fibrinolytic agent to a patient who is actively bleeding into their brain tissue would aggressively exacerbate the bleeding, leading to catastrophic neurological deterioration and almost certain death.

Additional Advanced Imaging Modalities

Once an intracranial hemorrhage has been safely ruled out by the non-contrast CT, many stroke centers will proceed immediately—while the patient is still on the scanner table—with advanced imaging, such as CT Angiography (CTA). A CTA uses intravenous contrast to visualize the cerebral vasculature, allowing the team to quickly identify Large Vessel Occlusions (LVOs) that may be amenable to mechanical thrombectomy. Furthermore, CT Perfusion (CTP) scans may be performed to quantitatively assess the volume of the core infarct (already dead tissue) versus the ischemic penumbra (tissue that is at risk but still salvageable). This advanced perfusion imaging is particularly crucial for evaluating patients who present in the extended 6 to 24-hour window.

Blood Glucose Assessment and Laboratory Tests

Alongside neuroimaging, the other mandatory diagnostic test that must be performed with extreme urgency is a point-of-care capillary blood glucose check. Ideally, this is completed by EMS in the prehospital setting, but if not, it must be done within minutes of ED arrival.

Severe hypoglycemia (abnormally low blood sugar) is a notorious "stroke mimic." It can produce profound, focal neurological deficits—such as unilateral weakness, aphasia, and altered mental status—that are clinically entirely indistinguishable from an acute ischemic stroke. If a patient's symptoms are determined to be driven by hypoglycemia, the immediate administration of intravenous dextrose will rapidly resolve the neurological deficits. This simple intervention averts the need for expensive, time-consuming imaging and prevents exposing the patient to the significant bleeding risks associated with fibrinolytic therapy.

In addition to the immediate glucose check, standard baseline laboratory tests should be drawn. These typically include a complete blood count (CBC), baseline coagulation studies (Prothrombin Time/INR, Activated Partial Thromboplastin Time), a basic metabolic panel, and cardiac biomarkers (such as troponin).

However, there is a critical caveat regarding laboratory testing in acute stroke care: Unless there is a specific clinical suspicion of a bleeding abnormality, or the patient is known to be taking systemic anticoagulants, the administration of IV fibrinolytic therapy should NEVER be delayed while waiting for the results of these laboratory tests. The only laboratory value that must be known prior to initiating fibrinolytics in a standard patient is the point-of-care blood glucose.